Trial Profile
Tolerability, pharmacokinetics, and pharmacodynamics of JNJ 39588146 in volunteers and patients with heart failure.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Sep 2012
Price :
$35
*
At a glance
- Drugs RT 400 (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Janssen Research & Development
- 09 Sep 2012 New trial record
- 29 Aug 2012 Results from part 3 of the study presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
- 29 Aug 2012 Results from part 2 of the study were presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.